Global Pleural Effusions Treatment Market Size By Type (Thoracentesis, Pleurodesis), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Pleural Effusions Treatment Market was valued at USD 5.6 billion in 2023 and is projected to reach USD 9.1 billion by 2031, growing at a CAGR of 6.3% during the forecast period (2023–2031). This growth is driven by the rising prevalence of pleural effusion-related conditions such as congestive heart failure, malignancies, and infections. Increasing awareness and diagnosis rates, coupled with the advancement of minimally invasive treatment options, are further boosting market demand. With a growing aging population and improving healthcare access in emerging economies, the demand for effective pleural effusions treatment continues to rise globally.

Drivers:

Rising Incidence of Chronic Diseases:

Conditions such as congestive heart failure, pneumonia, and cancers are key contributors to pleural effusions. The global increase in these diseases is fueling the demand for diagnosis and treatment.

Advancements in Treatment Modalities:

Minimally invasive procedures, such as thoracentesis and indwelling pleural catheterization, are becoming more prevalent due to reduced patient discomfort, faster recovery times, and lower hospitalization costs.

Growing Geriatric Population:

As the global elderly population increases, the incidence of pleural effusion rises concurrently, particularly due to comorbidities associated with age.

Restraints:

High Cost of Advanced Treatment:

Sophisticated interventions like pleurodesis or image-guided procedures can be costly, especially in low- and middle-income countries, limiting widespread adoption.

Limited Access in Developing Regions:

Lack of diagnostic infrastructure and trained professionals in underdeveloped areas hinders early detection and management of pleural effusions.

Opportunity:

Emerging Market Penetration:

Expanding healthcare infrastructure in Asia-Pacific, Latin America, and Africa presents new opportunities for market players to tap into underserved populations.

Innovation in Imaging and Diagnosis:

The development of portable ultrasound and AI-based diagnostic tools can facilitate earlier and more accurate detection, improving patient outcomes and expanding the market reach.

Market by System Type Insights:

The Thoracentesis Kits segment held the largest share in 2023 due to its widespread use in both diagnostic and therapeutic procedures. These kits are often the first-line treatment for pleural effusion, especially in emergency settings.

However, the Indwelling Pleural Catheters (IPCs) segment is anticipated to grow at the fastest rate. IPCs are increasingly preferred for recurrent effusions, particularly in cancer patients, due to their convenience, reduced need for hospitalization, and improved quality of life.

Market by End-use Insights:

Hospitals dominated the market in 2023, accounting for the majority of procedures performed. Their access to specialized staff and imaging technologies supports accurate diagnosis and timely treatment.

The Homecare Settings segment is expected to grow significantly due to the increasing use of IPCs, which allow patients to manage effusions in outpatient settings with minimal clinical supervision, enhancing patient comfort and reducing costs.

Market by Regional Insights:

North America led the market in 2023, driven by high awareness levels, better access to advanced treatments, and the presence of leading healthcare institutions.

Asia-Pacific is poised for the fastest growth, fueled by increasing healthcare investments, rising patient awareness, and a growing elderly population. Countries like India and China are witnessing a surge in cases due to increasing rates of infections and chronic illnesses.

Competitive Scenario:

Key players in the Global Pleural Effusions Treatment Market include Becton, Dickinson and Company, Cardinal Health, Rocket Medical plc, Cook Medical, Smiths Medical, Teleflex Incorporated, Medtronic plc, and Boston Scientific Corporation. These companies are actively investing in product innovation, geographic expansion, and strategic partnerships to enhance their market footprint.

Recent Developments:

In 2024, Teleflex launched an improved pleural drainage system featuring an integrated safety valve to reduce the risk of pneumothorax.

Boston Scientific expanded its thoracic care product line with a catheter system optimized for malignant pleural effusions.

In 2023, Becton, Dickinson and Company introduced a new ultrasound-guided thoracentesis kit for increased procedural accuracy.

Scope of Work – Global Pleural Effusions Treatment Market

Report Metric Details

Market Size (2023) USD 5.6 Billion

Projected Market Size (2031) USD 9.1 Billion

CAGR (2023–2031) 6.3%

Market Segments By System Type (Thoracentesis Kits, IPCs), By End-Use

Growth Drivers Rising chronic disease prevalence, aging population, minimally invasive treatment adoption

Opportunities Market expansion in emerging economies, AI-based diagnostics, homecare treatment solutions

Key Market Developments:

2024: Teleflex launched a safety-enhanced pleural drainage system for hospital use.

2023: Becton, Dickinson and Company rolled out an ultrasound-guided thoracentesis kit aimed at reducing complications.

2023: Rocket Medical announced a strategic partnership to expand its distribution in Southeast Asia.

FAQs:

What is the current market size of the Global